1. IgM paraprotein‐associated peripheral neuropathy: small CD20‐positive B‐cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness
- Author
-
Joshua Bomsztyk, Michael P. Lunn, Rajeev Gupta, Lucia Y. Chen, Evan Vitsaras, Stephen Keddie, and Shirley D'Sa
- Subjects
Male ,Paraproteinemias ,Plasma cell ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,Clinical significance ,Aged ,CD20 ,B-Lymphocytes ,biology ,business.industry ,Peripheral Nervous System Diseases ,Hematology ,Middle Aged ,Antigens, CD20 ,medicine.disease ,Lymphoma ,Peripheral neuropathy ,medicine.anatomical_structure ,Immunoglobulin M ,030220 oncology & carcinogenesis ,Immunology ,biology.protein ,Rituximab ,Bone marrow ,business ,Paraproteins ,030215 immunology ,medicine.drug - Abstract
IgM paraprotein-associated peripheral neuropathy (PN) in patients without overt evidence of lymphoma is a recognised clinical entity of unknown aetiology. Interrogating the bone marrow B-cell or plasma cell clones underlying paraproteinemic neuropathies may improve our understanding of both pathogenesis and treatment options. This retrospective observational analysis of IgM paraprotein-associated PN identified five patients with small pathological MYD88 L265P and CD20-positive B-cell clones in their bone marrow using multi-parametric flow cytometry, who have shown durable neurological response to rituximab. We posit that multi-parametric flow cytometry may be instrumental in identifying the cellular source of the paraprotein in IgM paraprotein-associated PN, and thus directing appropriate immunomodulatory therapy. Further understanding of these small pathological B-cell clones may also provide additional insight into mechanisms of monoclonal gammopathy of clinical significance overall.
- Published
- 2019
- Full Text
- View/download PDF